Trapidil modifies mesangial cell proliferation and collagen accumulation in anti-thymocyte serum (ATS)-induced glomerulonephritis

Platelet-derived growth factor and renal disease

PURPOSE OF REVIEW

This review focuses on the recent advances in our understanding of the role of platelet-derived growth factor (PDGF) in glomerular disease.

RECENT FINDINGS

Accumulating evidence indicates a critical involvement of PDGF receptor-β (PDGFR-β) signaling in glomerular disease. Augmented signaling via PDGFR-β is involved in the pathogenesis of IgA nephropathy. Therefore, targeting PDGFR-β signaling is a viable therapeutic strategy for glomerular diseases. However, current PDGFR-β antagonists are nonspecific, and their long-term effects remain to be elucidated. To develop effective intervention therapies targeting PDGF signaling, it is necessary to clarify the specific involvement of PDGF in the pathogenesis of glomerular disease. A novel PDGFR-β targeting mouse model has provided new insight into the postnatal role of PDGFR-β in aging-related mesangial sclerosis and the glomerular remodeling after nephrectomy. Furthermore, the same study indicated the redundancy of growth factor signals underlying glomerular remodeling. In this context, other studies have suggested a role for PDGFR-α signaling and collaborating growth factors to compensate for PDGFR-β in the kidney glomerulus.

SUMMARY

Intervention in growth factor signaling could be a valuable therapeutic strategy for kidney glomerular diseases. Further studies are required to characterize the pathogenesis of these diseases for the successful development of such a therapy.

Significance of increased accumulation of type VI collagen and transforming growth factor beta 1 in tubulointerstitial damage in hypertensive nephrosclerosis: an immunohistochemical study

The distribution of type VI collagen and transforming growth factor beta 1 (TGF beta 1) was studied by immunohistochemistry in 12 renal biopsy specimens of hypertensive nephrosclerosis and five control cases. In control kidneys, the immunostaining of type VI collagen was found in the mesangium, glomerular basement membrane and tubular basement membrane. For TGF beta 1, mesangium, glomerular basement membrane, tubular basement membrane and tubular epithelial cells stained positively in the control kidneys. In contrast to the control cases, markedly increased immunostaining for both type VI collagen and TGF beta 1 was consistently observed in tubulointerstitial damage in hypertensive nephrosclerosis. These immunohistochemical findings provide the evidence for a parallel increase of both type VI collagen and TGF beta 1 during the process of tubulointerstitial injury in hypertensive nephrosclerosis. From the results of the present study, it is speculated that TGF beta 1 may contribute to the tubulointerstitial injury by stimulating increased synthesis of various extracellular matrix including type VI collagen.